AIM ImmunoTech (NYSEAMERICAN:AIM) Given New $9.00 Price Target at Ascendiant Capital Markets

AIM ImmunoTech (NYSEAMERICAN:AIM) had its price target reduced by stock analysts at Ascendiant Capital Markets from $10.00 to $9.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Separately, Zacks Research lowered shares of AIM ImmunoTech from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $9.00.

AIM ImmunoTech Stock Performance

Shares of AIM opened at $0.41 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.01 and a current ratio of 1.01. AIM ImmunoTech has a twelve month low of $0.21 and a twelve month high of $20.35. The firm’s 50 day moving average price is $0.51 and its two-hundred day moving average price is $0.96. The firm has a market cap of $5.94 million, a P/E ratio of -0.06 and a beta of 1.18.

AIM ImmunoTech (NYSEAMERICAN:AIM) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.69) EPS for the quarter. The firm had revenue of $0.02 million for the quarter. On average, analysts forecast that AIM ImmunoTech will post -1.47 EPS for the current fiscal year.

Institutional Trading of AIM ImmunoTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in AIM. Sabby Management LLC bought a new stake in AIM ImmunoTech during the third quarter worth $79,000. DRW Securities LLC raised its position in AIM ImmunoTech by 60.6% during the fourth quarter. DRW Securities LLC now owns 69,545 shares of the company’s stock worth $79,000 after acquiring an additional 26,254 shares in the last quarter. Finally, Corient Private Wealth LLC bought a new stake in AIM ImmunoTech during the second quarter worth $87,000. 12.02% of the stock is owned by institutional investors.

AIM ImmunoTech Company Profile

AIM ImmunoTech is a clinical-stage biotechnology company focused on the development and commercialization of immune-modulating therapies for the treatment of viral infections and cancer. The company’s lead product candidate, Ampligen (rintatolimod), is a proprietary toll-like receptor 3 (TLR3) agonist that aims to enhance the body’s innate immune response. AIM ImmunoTech’s research and development efforts center on demonstrating the safety and efficacy of Ampligen as both a standalone therapy and in combination with other treatments.

In addition to its oncology and antiviral programs, the company is advancing clinical trials of Ampligen in patients with chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) and exploring potential applications for emerging viral threats.